Dr Mohamed Bouattour

Spécialité

Onco-hépatologie (thématique, carninome hépatocellulaire, cholangiocarcinome, cancers hépatiques rare)

Hôpital

Hôpital Beaujon (Clichy)

Derniers articles

• Second-Line TKI after First-Line Immunotherapy-based Treatment in Advanced HCC: Reconstructed IPD Meta-analysis. (12 mai 2026)
• Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer). (10 mai 2026)
• Vessels Encapsulating Tumor Clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab. (29 avr. 2026)
• Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data. (20 avr. 2026)
• Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular Carcinoma. (19 févr. 2026)